
|Slideshows|April 27, 2017
Best of MS: AAN 2017
The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.
Advertisement
Chosen studies presented at AAN 2017 included an evaluation of cortical lesions in MS; 6-year outcomes of treatment with alemtuzumab in RRMS patients; an investigation of a possible link between viral infections, vitamin D deficiency, and pediatric-onset MS; and a look at the possibility of fatigue and lower limb problems predicting progression from RRMS to SPMS.Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears PrecivityAD2 Alzheimer Blood Test for Symptomatic Patients 40 and Older
2
TEMPO-2 Data Supports Tavapadon’s Efficacy in Early-Stage Parkinson Disease
3
FDA Accepts Ecopipam NDA for Tourette Syndrome, Remlifanserin Receives Fast Track Designation for AD Psychosis, Alterity Reaches FDA Alignment on ATH434
4
Episode 173: Exploring the Emerging Role of GLP-1 Therapies in Neurology
5

















